1.Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial’ Clin Mol Hepatol 2024;30:807-823
Sun Young YIM ; Sung Hwan LEE ; Seung-Woo BAEK ; Bohwa SOHN ; Yun Seong JEONG ; Sang-Hee KANG ; Kena PARK ; Hyewon PARK ; Sunyoung S. LEE ; Ahmed O. KASEB ; Young Nyun PARK ; Sun-Hee LEEM ; Michael A. CURRAN ; Ji Hoon KIM ; Ju-Seog LEE
Clinical and Molecular Hepatology 2025;31(2):669-670
2.Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial’ Clin Mol Hepatol 2024;30:807-823
Sun Young YIM ; Sung Hwan LEE ; Seung-Woo BAEK ; Bohwa SOHN ; Yun Seong JEONG ; Sang-Hee KANG ; Kena PARK ; Hyewon PARK ; Sunyoung S. LEE ; Ahmed O. KASEB ; Young Nyun PARK ; Sun-Hee LEEM ; Michael A. CURRAN ; Ji Hoon KIM ; Ju-Seog LEE
Clinical and Molecular Hepatology 2025;31(2):669-670
3.Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial’ Clin Mol Hepatol 2024;30:807-823
Sun Young YIM ; Sung Hwan LEE ; Seung-Woo BAEK ; Bohwa SOHN ; Yun Seong JEONG ; Sang-Hee KANG ; Kena PARK ; Hyewon PARK ; Sunyoung S. LEE ; Ahmed O. KASEB ; Young Nyun PARK ; Sun-Hee LEEM ; Michael A. CURRAN ; Ji Hoon KIM ; Ju-Seog LEE
Clinical and Molecular Hepatology 2025;31(2):669-670
4.Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial
Sun Young YIM ; Sung Hwan LEE ; Seung-Woo BAEK ; Bohwa SOHN ; Yun Seong JEONG ; Sang-Hee KANG ; Kena PARK ; Hyewon PARK ; Sunyoung S. LEE ; Ahmed O. KASEB ; Young Nyun PARK ; Sun-Hee LEEM ; Michael A. CURRAN ; Ji Hoon KIM ; Ju-Seog LEE
Clinical and Molecular Hepatology 2024;30(4):807-823
Background/Aims:
Combination immunotherapy, exemplified by atezolizumab plus bevacizumab, has become the standard of care for inoperable hepatocellular carcinoma (HCC). However, the lack of predictive biomarkers and limited understanding of response mechanisms remain a challenge.
Methods:
Using data from the IMbrave150plus cohort, we applied an immune signature score (ISS) predictor to stratify HCC patients treated with atezolizumab plus bevacizumab or with sorafenib alone into potential high and low response groups. By applying multiple statistical approaches including a Bayesian covariate prediction algorithm, we refined the signature to 10 key genes (ISS10) for clinical use while maintaining similar predictive power to the full model. We further validated ISS10 in an independent HCC cohort treated with nivolumab plus ipilimumab.
Results:
The study identified a significant association between the ISS and treatment response. Among patients classified as high responders, those treated with the atezolizumab plus bevacizumab combination exhibited improved overall and progression-free survival as well as better objective response rate compared to those treated with sorafenib. We also observed a significant correlation between ISS10 and response to nivolumab plus ipilimumab treatment. Analysis of immune cell subpopulations revealed distinct characteristics associated with ISS subtypes. In particular, the ISS10 high subtype displayed a more favorable immune environment with higher proportions of antitumor macrophages and activated T-cells, potentially explaining its better response.
Conclusions
Our study suggests that ISS and ISS10 are promising predictive biomarkers for enhanced therapeutic outcomes in HCC patients undergoing combination immunotherapy. These markers are crucial for refining patient stratification and personalized treatment approaches to advance the effectiveness of standard-of-care regimens.
5.Erratum: Correction of Text in the Article “Effects of Hormone Replacement Therapy on Bone Mineral Density in Korean Adults With Turner Syndrome”
SunYoung KIM ; Heeyon KIM ; Inha LEE ; Euna CHOI ; JinKyung BAEK ; Jaekyung LEE ; Hae-Rim KIM ; Bo Hyon YUN ; Young Sik CHOI ; Seok Kyo SEO
Journal of Korean Medical Science 2024;39(32):e268-
6.Effects of Hormone Replacement Therapy on Bone Mineral Density in Korean Adults With Turner Syndrome
SunYoung KIM ; Heeyon KIM ; Inha LEE ; Euna CHOI ; JinKyung BAEK ; Jaekyung LEE ; Hae-Rim KIM ; Bo Hyon YUN ; Young Sik CHOI ; Seok Kyo SEO
Journal of Korean Medical Science 2024;39(1):e9-
Background:
Turner syndrome (TS) is a common chromosomal abnormality, which is caused by loss of all or part of one X chromosome. Hormone replacement therapy in TS is important in terms of puberty, growth and prevention of osteoporosis however, such a study has never been conducted in Korea. Therefore, the purpose of our study was to determine relationship between the starting age, duration of estrogen replacement therapy (ERT) in TS and develop a hormone replacement protocol suitable for the situation in Korea.
Methods:
This is retrospective study analyzed the medical records in TS patients treated at the Severance hospital, Yonsei University College of Medicine, Seoul, Korea from 1997 to 2019. Total of 188 subjects who had received a bone density test at least once were included in the study. Korean National Health and Nutrition Examination Survey (KNHANES) was used for achieving bone mineral density (BMD) of normal control group. Student’s t-test, MannWhitney U test, ANOVA and correlation analysis were performed using SPSS 18.0.
Results:
Each BMD measurement was significantly lower in women with TS than in healthy Korean women. Early start and longer duration of ERT is associated with higher lumbar spine BMD but not femur neck BMD. Femur neck BMD, but not lumbar spine BMD was significantly higher in women with mosaicism than 45XO group.
Conclusion
Early onset and appropriate duration of hormone replacement therapy is important for increasing bone mineral density in patients with Turner syndrome. Also, ERT affects differently to TS patients according to mosaicism.
7.Diagnostic Performance of LI-RADS v2018 versus KLCA-NCC 2018Criteria for Hepatocellular Carcinoma Using Magnetic Resonance Imaging with Hepatobiliary Agent: A Systematic Review and Meta-Analysis of Comparative Studies
Jaeseung SHIN ; Sunyoung LEE ; Ja Kyung YOON ; Won Jeong SON ; Yun Ho ROH ; Yong Eun CHUNG ; Jin-Young CHOI ; Mi-Suk PARK
Gut and Liver 2023;17(3):466-474
Background/Aims:
To compare the performance of the Liver Imaging Reporting and Data System (LI-RADS) v2018 and Korean Liver Cancer Association-National Cancer Center (KLCANCC) 2018 criteria for diagnosing hepatocellular carcinoma (HCC) using magnetic resonance imaging (MRI) with hepatobiliary agent (HBA).
Methods:
We searched the MEDLINE and EMBASE for studies from January 1, 2018, to October 20, 2021, that compared the diagnostic performance of two imaging criteria on HBA-MRI. A bivariate random-effects model was fitted to calculate the per-observation sensitivity and specificity, and the estimates of paired data were compared. Subgroup analysis was performed based on the observation size. Meta-regression analysis was also performed for study heterogeneity.
Results:
Of the six studies included, the pooled sensitivity of the definite HCC category of the KLCA-NCC criteria (82%; 95% confidence interval [CI], 74% to 90%; I 2 =84%) was higher than that of LR-5 of LI-RADS v2018 (65%; 95% CI, 52% to 77%; I 2 =96%) for diagnosing HCC (p<0.001), while the specificity was lower for KLCA-NCC criteria (87%; 95% CI, 84% to 91%; I 2 =0%) than LI-RADS v2018 (93%; 95% CI, 91% to 96%; I 2 =0%) (p=0.017). For observations sized ≥20 mm, the sensitivity was higher for KLCA-NCC 2018 than for LI-RADS v2018 (84% vs 74%, p=0.012), with no significant difference in specificity (81% vs 85%, p=0.451). The reference standard was a significant factor contributing to the heterogeneity of sensitivities.
Conclusions
The definite HCC category of KLCA-NCC 2018 provided a higher sensitivity and lower specificity than the LR-5 of LI-RADS v2018 for diagnosing HCC using MRI with HBA.
8.LI-RADS Version 2018 Treatment Response Algorithm: Diagnostic Performance after Transarterial Radioembolization for Hepatocellular Carcinoma
Jongjin YOON ; Sunyoung LEE ; Jaeseung SHIN ; Seung-seob KIM ; Gyoung Min KIM ; Jong Yun WON
Korean Journal of Radiology 2021;22(8):1279-1288
Objective:
To assess the diagnostic performance of the Liver Imaging Reporting and Data System (LI-RADS) version 2018 treatment response algorithm (TRA) for the evaluation of hepatocellular carcinoma (HCC) treated with transarterial radioembolization.
Materials and Methods:
This retrospective study included patients who underwent transarterial radioembolization for HCC followed by hepatic surgery between January 2011 and December 2019. The resected lesions were determined to have either complete (100%) or incomplete (< 100%) necrosis based on histopathology. Three radiologists independently reviewed the CT or MR images of pre- and post-treatment lesions and assigned categories based on the LI-RADS version 2018 and the TRA, respectively. Diagnostic performances of LI-RADS treatment response (LR-TR) viable and nonviable categories were assessed for each reader, using histopathology from hepatic surgeries as a reference standard. Inter-reader agreements were evaluated using Fleiss κ.
Results:
A total of 27 patients (mean age ± standard deviation, 55.9 ± 9.1 years; 24 male) with 34 lesions (15 with complete necrosis and 19 with incomplete necrosis on histopathology) were included. To predict complete necrosis, the LR-TR nonviable category had a sensitivity of 73.3–80.0% and a specificity of 78.9–89.5%. For predicting incomplete necrosis, the LR-TR viable category had a sensitivity of 73.7–79.0% and a specificity of 93.3–100%. Five (14.7%) of 34 treated lesions were categorized as LR-TR equivocal by consensus, with two of the five lesions demonstrating incomplete necrosis. Interreader agreement for the LR-TR category was 0.81 (95% confidence interval: 0.66–0.96).
Conclusion
The LI-RADS version 2018 TRA can be used to predict the histopathologic viability of HCCs treated with transarterial radioembolization.
9.LI-RADS Version 2018 Treatment Response Algorithm: Diagnostic Performance after Transarterial Radioembolization for Hepatocellular Carcinoma
Jongjin YOON ; Sunyoung LEE ; Jaeseung SHIN ; Seung-seob KIM ; Gyoung Min KIM ; Jong Yun WON
Korean Journal of Radiology 2021;22(8):1279-1288
Objective:
To assess the diagnostic performance of the Liver Imaging Reporting and Data System (LI-RADS) version 2018 treatment response algorithm (TRA) for the evaluation of hepatocellular carcinoma (HCC) treated with transarterial radioembolization.
Materials and Methods:
This retrospective study included patients who underwent transarterial radioembolization for HCC followed by hepatic surgery between January 2011 and December 2019. The resected lesions were determined to have either complete (100%) or incomplete (< 100%) necrosis based on histopathology. Three radiologists independently reviewed the CT or MR images of pre- and post-treatment lesions and assigned categories based on the LI-RADS version 2018 and the TRA, respectively. Diagnostic performances of LI-RADS treatment response (LR-TR) viable and nonviable categories were assessed for each reader, using histopathology from hepatic surgeries as a reference standard. Inter-reader agreements were evaluated using Fleiss κ.
Results:
A total of 27 patients (mean age ± standard deviation, 55.9 ± 9.1 years; 24 male) with 34 lesions (15 with complete necrosis and 19 with incomplete necrosis on histopathology) were included. To predict complete necrosis, the LR-TR nonviable category had a sensitivity of 73.3–80.0% and a specificity of 78.9–89.5%. For predicting incomplete necrosis, the LR-TR viable category had a sensitivity of 73.7–79.0% and a specificity of 93.3–100%. Five (14.7%) of 34 treated lesions were categorized as LR-TR equivocal by consensus, with two of the five lesions demonstrating incomplete necrosis. Interreader agreement for the LR-TR category was 0.81 (95% confidence interval: 0.66–0.96).
Conclusion
The LI-RADS version 2018 TRA can be used to predict the histopathologic viability of HCCs treated with transarterial radioembolization.
10.Physical Activity Patterns and Their Associated Factors Measured by Global Physical Activity Questionnaire Survey among Korean
Kyungha MIN ; Yun Hwan OH ; Sun Woo KIM ; Ho Jun KIM ; Houbuem LEE ; Sung Ha LEE ; Sunyoung KIM ; Jeong Sang LEE ; Jong Seung KIM ; Bumjo OH
The Korean Journal of Sports Medicine 2020;38(1):1-11
Research on physical activity and health is actively being conducted. In the Korea National Health and Nutrition Examination Survey (KNHANES), the Global Physical Activity Questionnaire (GPAQ) was newly introduced in 2014. The purpose of this study was to investigate the levels of physical activity and related factors in Koreans who were assessed through the GPAQ by dividing the physical activity by occupation, leisure, and transport domain. This study used data from the KNHANES (2014–2016), the study population of which included 17,357 participants aged 12 to 80 years. We compared the differences in physical activity by sociodemographic factors, health-related factors, and psychological health-related factors. Moreover, we also compared the mean metabolic equivalent of task and daily sitting time according to physical activity domain by sex and age group. Finally, we investigated the sociodemographic factors, health-related factors, and psychological health-related factors that significantly affect the average physical activity per week. The various factors were found to differ in the frequency of physical activity levels. In addition, there was a difference in the amount of physical activity per occupation, leisure, and transport domain in each age group. Finally, age, sex, high-density lipoprotein cholesterol levels, arthritis, allergic rhinitis and sinusitis, sleeping time, and perceived health status significantly affected physical activity. The levels of physical activity significantly differed by sociodemographic factors, health-related factors, and psychological health-related factors. There was also a difference in the physical activity levels according to the age and sex per each domain of physical activity.
Arthritis
;
Cholesterol
;
Humans
;
Korea
;
Leisure Activities
;
Lipoproteins
;
Metabolic Equivalent
;
Motor Activity
;
Nutrition Surveys
;
Occupations
;
Physical Fitness
;
Public Health
;
Rhinitis, Allergic
;
Risk Factors
;
Sinusitis
;
Social Determinants of Health
;
Surveys and Questionnaires

Result Analysis
Print
Save
E-mail